SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

AVAX TECHNOLOGIES INC (AVXT)

AVXT RSS Feed
Add AVXT Price Alert      Hide Sticky   Hide Intro
Moderator: johnny canuck
Search This Board:
Last Post: 12/7/2016 11:04:58 PM - Followers: 32 - Board type: Free - Posts Today: 0

 

Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
CEO: Adele Sommerfeld
BOD: Andrew W. Dahl Sc.D.; Serge Morrell
 
 
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

 


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


 

Press Releases & AVAX Information:

https://en.wikipedia.org/wiki/Avax_Technologies

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551891/

http://www.ncbi.nlm.nih.gov/pubmed/22854662

http://www.clinicaltrials.gov/ct2/show/NCT00477906?term=MVax&rank=1

http://clinicaltrials.gov/show/NCT00660101

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20130309271&OS=20130309271&RS=20130309271

http://www.biotechblog.org/Tags/cancer-treatment-centers-of-america/

http://www.thefreelibrary.com/AVAX+Technologies+Announces+Collaboration+with+Cancer+Treatment...-a0159564876

http://www.reuters.com/article/2014/01/08/ctca-trial-cancer-idUSnPnDChVKwJ+16d+PRN20140108

http://ih.advfn.com/p.php?pid=nmona&article=61013370

http://www.bizjournals.com/philadelphia/blog/health-care/2014/02/ovarian-cancer-vaccine-testing-expands.html

http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing

 
By

Published: Aug 4, 2015 7:31 p.m. ET

Share
 
 
 
 

PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.


AVAX TECHNOLOGIES WEBSITE IS NOW ACTIVE:    WWW.AVAX-TECH.COM/
 

AVAX TECHNOLOGIES, INC APPOINTS NEW CEO: ADELE SOMMERFELD 10/19/2015
http://www.prnewswire.com/news-releases/avax-technologies-inc-announces-the-appointment-of-chief-executive-officer-300161646.html



 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#1342  Sticky Note http://www.prnewswire.com/news-releases/avax-technologies-announces-results-of-i johnny canuck 01/26/16 07:32:21 PM
#1481   Our hard-earned monies took them this far and Geoman1 12/07/16 11:04:58 PM
#1480   You are right ... we need of tencoin 12/07/16 09:34:39 AM
#1479   You are right ... we need of tencoin 12/07/16 09:30:59 AM
#1478   Bingo..... they don't have much farther to go now. johnny canuck 12/06/16 10:19:54 AM
#1477   Bingo..... they don't have much farther to go now. johnny canuck 12/06/16 10:19:43 AM
#1476   Bingo...shit strikes again....crash.... Geoman1 12/01/16 02:38:45 PM
#1475   Come on baby...short it again...show us what you Geoman1 11/30/16 11:08:31 PM
#1474   Just waiting for the final crash and smash...it Geoman1 11/29/16 07:28:57 PM
#1473   $1,300.00 left out of 100 grand and counting Geoman1 11/28/16 10:21:54 AM
#1472   1,600 left out of 100,000 g's. May all Geoman1 11/21/16 02:28:05 PM
#1471   Just like all the rest, I believe they Geoman1 10/29/16 03:18:42 PM
#1470   Hell...... they don't even answer the phone. If johnny canuck 10/26/16 12:50:30 PM
#1469   1,750 left out of 100 G's placed. Eat Geoman1 10/25/16 02:21:20 PM
#1468   Looks like there are more games being played Geoman1 10/21/16 11:39:25 AM
#1467   See how they dump tomorrow. Crooked MM's johnny canuck 10/04/16 10:04:20 PM
#1466   Waiting for Monday's shorting dump - wait and johnny canuck 10/02/16 10:59:37 PM
#1465   Told ya! Crooked MM's. johnny canuck 09/29/16 11:15:24 AM
#1464   Up today and shorting dump tomorrow. Crooked MM's. johnny canuck 09/28/16 04:46:48 PM
#1463   MM's doing as expected. Crooked MM's johnny canuck 09/26/16 11:01:38 AM
#1462   See my last couple of posts. Crooked MM's johnny canuck 09/22/16 01:19:08 PM
#1461   F_________K! Geoman1 09/22/16 01:01:22 PM
#1460   WOW! Up she goes. Waiting for the shorting johnny canuck 09/21/16 01:36:57 PM
#1459   Yup!! Just as predicted. Crooked MM's Brought the price johnny canuck 09/19/16 10:02:56 AM
#1458   MM's working this thing over pretty hard today. johnny canuck 09/12/16 03:14:20 PM
#1457   Wow! Nice "SHORTING" work today. johnny canuck 09/09/16 04:11:52 PM
#1456   I do not believe anyone is in the Geoman1 08/26/16 12:49:51 PM
#1455   sorry sir, so many of us in the akika 08/26/16 01:15:10 AM
#1454   100 G's to now 2.4 G's. These people Geoman1 08/25/16 09:30:53 PM
#1453   Hello, anybody home>??? akika 08/20/16 08:53:05 PM
#1452   please turn the lights off when you are done. akika 08/17/16 11:51:35 PM
#1451   This thing isn't getting too manipulated........nooooooo. johnny canuck 08/17/16 07:29:13 PM
#1450   sad, I guess everyone zapped. akika 08/12/16 03:36:11 PM
#1449   are you still here? akika 08/11/16 08:39:07 PM
#1448   I think the circus left town with the johnny canuck 07/30/16 08:54:37 PM
#1447   What a freakin AVXT circus today Geoman1 07/21/16 03:17:30 PM
#1446   My rationale is right now, I do not Geoman1 07/20/16 10:27:14 AM
#1445   http://www.consumereagle.com/avax-techs-incorporated-otcmktsavxt-shorts-decrease katter 07/19/16 11:45:47 PM
#1444   Sir, are you still here? how many shares akika 07/19/16 10:24:31 PM
#1443   I would forget penny stocks, buy good stocks katter 07/19/16 08:23:46 PM
#1442   Thanks, its 1959 Thats TurningPoint 07/18/16 01:13:46 PM
#1441   Why don't you ask us all? He or katter 07/18/16 01:06:36 PM
#1440   How are you sir? Sorry for your TurningPoint 07/17/16 08:51:32 PM
#1439   Did you try calling Mrs. Sommerfeld? This is medimpact 07/15/16 01:16:30 PM
#1438   sorry about everything sir, I wish you better akika 07/12/16 09:29:02 PM
#1437   I am not grateful. I am disgusted. I Geoman1 07/11/16 06:47:32 PM
#1436   Be grateful sir, 3.2 is better than nothing. akika 07/11/16 04:11:39 PM
#1435   In flames...100G's to 3.2 G's. This is a Geoman1 07/11/16 01:35:34 PM
#1434   I'm sorry, I cannot figure out who is tencoin 07/04/16 09:23:05 AM
#1433   Well Goosey, johnny canuck 07/03/16 08:24:40 PM
#1432   Thanks JC, I appreciate your investigation. Keep the faith. Goosey 07/03/16 07:06:05 PM
PostSubject